| Schedule of Condensed Balance Sheets |
Condensed balance sheets
| | |
As of December 31, | |
| | |
2024 | | |
2025 | |
| | |
US$ | | |
US$ | |
| ASSETS | |
| | |
| |
| Non-current assets: | |
| | |
| |
| Investment in a subsidiary | |
| 1 | | |
| 1 | |
| Amounts due from a subsidiary | |
| 2,585,944 | | |
| 15,696,933 | |
| Deferred offering cost | |
| 620,193 | | |
| — | |
| Total non-current assets | |
| 3,206,138 | | |
| 15,696,934 | |
| TOTAL ASSETS | |
| 3,206,138 | | |
| 15,696,934 | |
| | |
| | | |
| | |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | |
| Amounts due to a director | |
| 1 | | |
| 1 | |
| Total current liabilities | |
| 1 | | |
| 1 | |
| TOTAL LIABILITIES | |
| 1 | | |
| 1 | |
| | |
| | | |
| | |
| Commitments and contingencies (Note 17) | |
| | | |
| | |
| | |
| | | |
| | |
| Shareholders’ equity | |
| | | |
| | |
| Class A Ordinary shares, US$0.0025 par value, 18,000,000 shares authorized, and 265,300 shares and 2,905,300 shares issued and outstanding as of December 31, 2024 and 2025, respectively* | |
| 663 | | |
| 7,263 | |
| Class B Ordinary shares, US$0.0025 par value, 2,000,000 shares authorized, and 160,000 shares and 160,000 shares outstanding as of December 31, 2024 and 2025, respectively* | |
| 400 | | |
| 400 | |
| Additional paid-in capital | |
| 3,583,180 | | |
| 17,152,709 | |
| Accumulated losses | |
| (378,106 | ) | |
| (1,463,439 | ) |
| Total shareholders’ equity | |
| 3,206,137 | | |
| 15,696,933 | |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| 3,206,138 | | |
| 15,696,934 | |
| * | Giving retroactive effect to (i) a share re-designation of 900,000,000 Class A ordinary shares and 100,000,000 Class B ordinary shares on August 7, 2025 and reverse stock split of the Company’s Class A ordinary shares and Class B ordinary shares on 1-for-50 basis, which became effective on March 6, 2026. |
|
| Schedule of Condensed Statements of Loss |
Condensed statements of loss
| | |
Years ended December 31, | |
| | |
2024 | | |
2025 | |
| | |
US$ | | |
US$ | |
| OPERATING EXPENSES | |
| | |
| |
| Legal and professional fees | |
| — | | |
| (205,333 | ) |
| Staff costs and employee benefits | |
| — | | |
| (880,000 | ) |
| Others | |
| — | | |
| — | |
| TOTAL OPERATING EXPENSES | |
| — | | |
| (1,085,333 | ) |
| Income tax expense | |
| — | | |
| — | |
| NET LOSS | |
| — | | |
| (1,085,333 | ) |
|
| Schedule of Condensed Statements of Cash Flows |
Condensed statements of cash flows
| | |
Years ended December 31, | |
| | |
2024 | | |
2025 | |
| | |
US$ | | |
US$ | |
| Cash flows from operating activities: | |
| | |
| |
| Net loss | |
| — | | |
| (1,085,333 | ) |
| Adjustments to reconcile net loss to net cash provided by operating activities | |
| | | |
| | |
| Share-based payments | |
| — | | |
| 1,085,333 | |
| Cash used in operating activities | |
| — | | |
| — | |
| | |
| | | |
| | |
| Cash flows from financing activities: | |
| | | |
| | |
| Proceeds from initial public offerings | |
| 4,019,673 | | |
| — | |
| Proceeds from placements | |
| — | | |
| 12,344,129 | |
| Payment for deferred offering cost | |
| (620,193 | ) | |
| — | |
| Advance from (to) a subsidiary | |
| (3,390,220 | ) | |
| (12,344,129 | ) |
| Repayment to a director | |
| (9,260 | ) | |
| — | |
| Settlement of subscription receivables from shareholders | |
| — | | |
| — | |
| Cash provided by financing activities | |
| — | | |
| — | |
| | |
| | | |
| | |
| Net change in cash and cash equivalents | |
| | | |
| | |
| Cash and cash equivalents at beginning of the year | |
| — | | |
| — | |
| Cash and cash equivalents at the end of the year | |
| — | | |
| — | |
|